|
Heart failure
|
0.100 |
Biomarker
|
disease |
BEFREE |
The mediators that were identified support existing and novel hypothesized mechanisms for the prevention of heart failure with sodium glucose cotransporter 2 inhibitors.
|
31676303 |
2020 |
|
Heart failure
|
0.100 |
Biomarker
|
disease |
BEFREE |
There were no differences in the risk ratios between men and women, SGLT2 versus control (placebo), for vascular efficacy outcomes or death (all P for interaction ≥.12), with clear protection shown against major adverse cardiovascular events, heart failure, vascular death and total mortality.
|
31486272 |
2020 |
|
Heart failure
|
0.100 |
Biomarker
|
disease |
BEFREE |
Empagliflozin, an SGLT2 inhibitor, has shown remarkable reductions in cardiovascular mortality and heart failure admissions (EMPA-REG OUTCOME).
|
31837891 |
2020 |
|
Heart failure
|
0.100 |
Biomarker
|
disease |
BEFREE |
Amongst those with type 2 diabetes mellitus who did not have established cardiovascular disease but did present with multiple risk factors, SGLT2 inhibitors lowered the combined endpoint of cardiovascular death or hospitalization for heart failure but had little impact on the occurrence of major adverse cardiac events.
|
31839265 |
2020 |
|
Heart failure
|
0.100 |
Biomarker
|
disease |
BEFREE |
Emerging data have demonstrated that sodium-glucose cotransporter-2 (SGLT2) inhibitors prevent cardiovascular events, especially heart failure-associated endpoints.
|
31725011 |
2020 |
|
Heart failure
|
0.100 |
Biomarker
|
disease |
BEFREE |
Our results demonstrate that SGLT2 inhibitors may be novel therapeutics against reduced exercise endurance capacity in HF, by improving mitochondrial fatty acid oxidation in skeletal muscle.
|
31738936 |
2020 |
|
Heart failure
|
0.100 |
Biomarker
|
disease |
BEFREE |
Sodium-glucose cotransporter 2 (SGLT2) inhibitors have been shown to improve cardiovascular outcomes including hospitalization for heart failure and mortality in people with and without diabetes.<sup>1, 2</sup> The mechanism(s) underlying this benefit remain unclear.
|
31707794 |
2020 |
|
Heart failure
|
0.100 |
Biomarker
|
disease |
BEFREE |
Using data from the US Get With The Guidelines (GWTG)-Heart Failure registry, we evaluated the proportion of patients with DM and HF eligible for SGLT-2 inhibitor therapy based on the clinical trial criteria and the US FDA labelling criteria.
|
31747132 |
2020 |
|
Heart failure
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Traditional management of diabetes mellitus has focused on glycemic control, beginning with lifestyle changes, followed by metformin, and then other classes of antiglycemic agents.<sup>1</sup> Sodium glucose co-transporter 2 (SGLT2) inhibitors reduce cardiovascular (CV) events, including CV death, myocardial infarction (MI) and heart failure, and slow progression of renal dysfunction, including prevention of end-stage kidney disease (ESKD).<sup>2-3</sup> Because initial clinical trials included mostly patients with baseline HbA1c >7%, current guidelines have recommended this class as add-on therapy for patients whose HbA1c is not at goal, typically ≥7%.<sup>1</sup> We hypothesized that there would be similar benefits on CV and renal endpoints regardless of baseline HbA1c, including those with HbA1c <7%.
|
31707795 |
2020 |
|
Heart failure
|
0.100 |
Biomarker
|
disease |
BEFREE |
Accordingly, SGLT-2 inhibitors could be recommended to prevent HF hospitalisation in patients with T2DM and established cardiovascular disease or with multiple risk factors.
|
31816162 |
2020 |
|
Heart failure
|
0.100 |
Biomarker
|
disease |
BEFREE |
Unraveling the mechanisms behind the beneficial actions of SGLT2 inhibitors may not only contribute to a better understanding of the pathophysiology of cardiovascular diseases but also enable repurposing of gliflozins to improve the routine management of HF patients with or without T2D.
|
31721613 |
2020 |
|
Heart failure
|
0.100 |
Biomarker
|
disease |
BEFREE |
Furthermore, the benefit of SGLT-2 inhibitors in a population of patients with HF yet without diabetes remains to be demonstrated across multiple trials.
|
31630988 |
2020 |
|
Heart failure
|
0.100 |
Biomarker
|
disease |
BEFREE |
Robust data from stable outpatient cohorts indicate that the SGLT2 inhibitors are associated with clinically meaningful reductions in major adverse cardiovascular events, lower rates of hospitalization for heart failure, and a reduction in major kidney outcomes There is however a lack of information on how to initiate and manage SGLT2 inhibitors in an acute in-patient setting.
|
31804229 |
2020 |
|
Heart failure
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Ongoing clinical trials will uncover the potential benefit of SGLT2 inhibitors in patients with prevalent heart failure with or without diabetes mellitus.
|
31494110 |
2020 |
|
Heart failure
|
0.100 |
Biomarker
|
disease |
BEFREE |
The role of sodium glucose cotransporter-2 (SGLT-2) inhibitors in heart failure and chronic kidney disease in type 2 diabetes.
|
30767677 |
2019 |
|
Heart failure
|
0.100 |
Biomarker
|
disease |
BEFREE |
The most impressive finding has been the substantial and consistent risk reduction in HF hospitalization seen across 4 trials of sodium glucose cotransporter 2 inhibitors.
|
31841369 |
2019 |
|
Heart failure
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Based on such evidence, the recent guidelines for the management of type 2 diabetes now suggest that SGLT-2 inhibitors should be preferred among oral agents in combination with metformin, in patients at increased cardiovascular risk, chronic kidney disease or heart failure.
|
31663470 |
2019 |
|
Heart failure
|
0.100 |
Biomarker
|
disease |
BEFREE |
SGLT-2 inhibitors showed significant reduction in hospitalization for heart failure events (RR 0.72; 95% CI 0.6-0.86) compared to placebo.
|
30713085 |
2019 |
|
Heart failure
|
0.100 |
Biomarker
|
disease |
BEFREE |
Whilst the lack of benefits on MACE may seem in contrast with the results of previous SGLT-2 inhibitors cardiovascular outcome trials, DECLARE clearly delineates the real cardiovascular effects of SGLT-2 inhibitors, which mainly tackle heart failure.
|
30604504 |
2019 |
|
Heart failure
|
0.100 |
Biomarker
|
disease |
BEFREE |
In the Horizon membership, we confirmed that SGLT-2 inhibitors reduce HF hospitalizations, resulting in reduced medical spending and savings in total cost of care.
|
31778623 |
2019 |
|
Heart failure
|
0.100 |
Biomarker
|
disease |
BEFREE |
SGLT2 inhibitors are being actively studied in the treatment of patients with HF, including in those without diabetes mellitus.
|
30704605 |
2019 |
|
Heart failure
|
0.100 |
Biomarker
|
disease |
BEFREE |
Based on the available evidence, we conclude that SGLT-2 inhibitors represent an evidence-based therapeutic option for the primary prevention of heart failure hospitalization and secondary prevention of CVD in patients with T2DM, and should be considered early on in the treatment algorithm for patients with multiple risk factors, or those with established CVD.
|
31264765 |
2019 |
|
Heart failure
|
0.100 |
Biomarker
|
disease |
BEFREE |
SGLT2 inhibitors appear to be particularly beneficial in patients with heart failure.
|
31583647 |
2019 |
|
Heart failure
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Loop diuretic use among patients with heart failure and type 2 diabetes treated with sodium glucose cotransporter-2 inhibitors.
|
31176543 |
2019 |
|
Heart failure
|
0.100 |
Biomarker
|
disease |
BEFREE |
The sodium-glucose cotransporter-2 (SGLT2) inhibitor canagliflozin has been shown to reduce major cardiovascular events in type 2 diabetic patients, with a pronounced decrease in hospitalization for heart failure (HF) especially in those with HF at baseline.
|
30992077 |
2019 |